Brought to you by 
AMAG pays $674mm in cash and stock to buy Lumara Health
26 Apr 2021
Executive Summary
AMAG Pharmaceuticals Inc. (sells a therapy for kidney disease-related anemia and one for oral mucositis) will pay $600mm in cash and issue 3.2mm shares (valued at $74mm) to acquire Lumara Health Inc. (formerly KV Pharmaceutical) and its wholly owned subsidiaries, including key asset Makena (hydroxyprogesterone caproate). The transaction also includes up to $350mm in sales-based earn-outs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AMAG pays $674mm in cash and stock to buy Lumara Health
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice